Trending Topics in Gastroenterology | GastroAGI

Type 2 Diabetes Accelerates Liver Fibrosis in Chronic Hepatitis B with Fatty Liver: Hepatology | May 2026

Introduction: Chronic hepatitis B (CHB), hepatic steatosis, and type 2 diabetes mellitus (T2DM) frequently coexist, creating a growing clinical challenge. This multinational study evaluated whether T2DM independently influences liver histology in treatment-naïve CHB patients with concurrent hepatic steatosis. Why was this study needed? • The coexistence of CHB, fatty liver, and T2DM is becoming increasingly common. • The impact of diabetes on liver fibrosis in CHB remains poorly understood. • Viral and metabolic factors may contribute differently to liver injury. • Better risk stratification is needed for patients with dual liver disease. • Understanding these interactions may improve long-term management. Results: • Type 2 diabetes independently increased the risk of significant liver fibrosis in treatment-naïve CHB patients with hepatic steatosis. • HBeAg positivity was primarily associated with hepatic inflammation, whereas higher BMI predicted more severe hepatic steatosis, highlighting distinct roles of viral and metabolic factors. • These findings demonstrate that diabetes contributes to fibrosis progression independently of other metabolic syndrome components. Clinical Impact: This international study reinforces the need for a dual therapeutic approach in CHB patients with fatty liver. While antiviral therapy remains essential for viral control, aggressive management of diabetes may be equally important to slow fibrosis progression and improve long-term liver outcomes. Bottom Line: Type 2 diabetes is an independent driver of liver fibrosis in chronic hepatitis B patients with hepatic steatosis. Optimal management should address both viral replication and metabolic risk factors, particularly diabetes, to reduce the risk of progressive liver disease.

A Novel Gut-Targeted Therapy for MASH (DT-109): Journal of Clinical Investigation | July 2026

Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) remains a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma, with limited treatment options. This study evaluated DT-109, a novel glycine-based tripeptide, as a gut-targeted therapy aimed at restoring the gut–liver axis and reversing MASH. Why was this study needed? • Current therapies only partially address MASH progression. • Gut barrier dysfunction is increasingly recognized as a key driver of MASH. • Ammonia-producing gut bacteria may contribute to liver inflammation and fibrosis. • Novel therapies targeting the gut–liver axis are urgently needed. • Safe treatments with both hepatic and cardiometabolic benefits are desirable. Results: • DT-109 reversed MASH in animal models by restoring intestinal barrier integrity and reducing liver inflammation. • The drug suppressed Clostridium perfringens, reduced intestinal ammonia production, and prevented the systemic translocation of harmful microbial products that promote hepatic inflammation. • In non-human primates, DT-109 significantly improved liver inflammation and MASH severity, suggesting strong translational potential. In addition, previous studies suggest potential cardiovascular benefits, including reduced atherosclerosis and vascular calcification. Clinical Impact: DT-109 introduces a novel therapeutic concept by targeting the gut microbiome and intestinal barrier rather than the liver alone. If confirmed in human trials, this approach could represent a new generation of gut-directed therapies for MASH, with potential benefits extending to cardiovascular disease and other disorders linked to gut barrier dysfunction. Bottom Line: DT-109 treats MASH by repairing the gut–liver axis rather than directly targeting the liver. By restoring intestinal barrier function and reducing ammonia-producing gut bacteria, it represents a promising new therapeutic strategy that now warrants clinical evaluation in humans.

DT-109- A Novel Gut-Targeted Therapy for MASH: JCI | July 2026

Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) remains a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma, with limited treatment options. This study evaluated DT-109, a novel glycine-based tripeptide, as a gut-targeted therapy aimed at restoring the gut–liver axis and reversing MASH. Why was this study needed? • Current therapies only partially address MASH progression. • Gut barrier dysfunction is increasingly recognized as a key driver of MASH. • Ammonia-producing gut bacteria may contribute to liver inflammation and fibrosis. • Novel therapies targeting the gut–liver axis are urgently needed. • Safe treatments with both hepatic and cardiometabolic benefits are desirable. Results: • DT-109 reversed MASH in animal models by restoring intestinal barrier integrity and reducing liver inflammation. • The drug suppressed Clostridium perfringens, reduced intestinal ammonia production, and prevented the systemic translocation of harmful microbial products that promote hepatic inflammation. • In non-human primates, DT-109 significantly improved liver inflammation and MASH severity, suggesting strong translational potential. In addition, previous studies suggest potential cardiovascular benefits, including reduced atherosclerosis and vascular calcification. Clinical Impact: DT-109 introduces a novel therapeutic concept by targeting the gut microbiome and intestinal barrier rather than the liver alone. If confirmed in human trials, this approach could represent a new generation of gut-directed therapies for MASH, with potential benefits extending to cardiovascular disease and other disorders linked to gut barrier dysfunction. Bottom Line: DT-109 treats MASH by repairing the gut–liver axis rather than directly targeting the liver. By restoring intestinal barrier function and reducing ammonia-producing gut bacteria, it represents a promising new therapeutic strategy that now warrants clinical evaluation in humans.

Tirzepatide vs SGLT2i in MASLD: Hepatology International | July 2026

Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to obesity, diabetes, and cardiovascular disease. While both tirzepatide and SGLT2 inhibitors improve metabolic health, comparative real-world data on long-term liver and cardiovascular outcomes have been limited. This large propensity-matched study compared these therapies in routine clinical practice. Why was this study needed? • Head-to-head real-world comparisons between tirzepatide and SGLT2 inhibitors are lacking. • MASLD requires therapies that improve both hepatic and cardiometabolic outcomes. • Long-term clinical outcome data beyond weight loss are limited. • Real-world evidence is needed to complement randomized clinical trials. • Better treatment selection could improve survival and reduce liver-related complications. Results: • Tirzepatide significantly reduced all-cause mortality, hospitalizations, major cardiovascular events, and major adverse liver outcomes compared with SGLT2 inhibitors. • These clinical benefits were observed at 1 year and remained consistent through 3 years of follow-up. • The findings suggest that tirzepatide may provide broader cardiometabolic and hepatic protection than SGLT2 inhibitors in patients with MASLD. Clinical Impact: This large real-world study supports tirzepatide as a highly effective therapeutic option for patients with MASLD and metabolic comorbidities. Beyond weight reduction and glycemic control, tirzepatide appears to improve both liver-related and cardiovascular outcomes, reinforcing its emerging role in the comprehensive management of MASLD. Bottom Line: Tirzepatide outperformed SGLT2 inhibitors across multiple clinically meaningful outcomes in patients with MASLD. These findings strengthen the growing evidence supporting tirzepatide as a preferred metabolic therapy for patients with fatty liver disease and associated cardiometabolic risk, while awaiting confirmation from prospective randomized trials.

Early Weight Regain After GLP-1 RA Discontinuation: Diabetes, Obesity and Metabolism | July 2026

Introduction: GLP-1 receptor agonists (GLP-1RAs) have revolutionized obesity treatment, producing substantial weight loss and cardiometabolic benefits. However, many patients discontinue therapy because of cost, adverse effects, or limited access, and weight regain frequently follows. This review summarizes current evidence on the mechanisms of post-GLP-1 weight regain and explores emerging treatment de-escalation strategies. Why was this review needed? • Weight regain after stopping GLP-1RAs is common and poorly understood. • There is limited guidance on how to safely discontinue GLP-1 therapy. • The biological mechanisms driving rebound weight gain remain incompletely defined. • Strategies to minimize early weight regain are urgently needed. • Evidence is emerging that gradual treatment de-escalation may be preferable to abrupt discontinuation. Key Takeaways: • Most weight regain occurs within the first few months after stopping GLP-1RA therapy, making this a critical period for intervention. • Weight regain is driven by the return of appetite, increased hunger hormones (particularly ghrelin), and loss of pharmacologic appetite suppression. • Improvements in blood glucose, blood pressure, and lipid profile also gradually diminish after treatment cessation. • Abrupt discontinuation may create a biological mismatch between increased appetite and the sudden loss of GLP-1 activity, accelerating weight regain. • Emerging evidence suggests that lower-intensity maintenance therapy may better preserve weight loss than abrupt treatment withdrawal. • The role of structured dose tapering remains promising but has not yet been confirmed in prospective clinical trials. Clinical Impact: Obesity should increasingly be viewed as a chronic disease requiring long-term management rather than a condition treated with short-term pharmacotherapy. Patients discontinuing GLP-1RAs should receive close follow-up, lifestyle support, and individualized treatment plans during the early post-cessation period when the risk of weight regain is greatest. Bottom Line: Weight regain after GLP-1RA discontinuation is substantial and occurs predominantly during the early months after stopping therapy. Until stronger evidence becomes available, gradual treatment de-escalation or maintenance strategies may represent a more rational approach than abrupt discontinuation.

Incretin-Based Therapy for MASH: Metabolic Target Organ Damage | July 2026

Introduction: The treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) is evolving rapidly with the emergence of incretin-based therapies. Beyond improving weight and glycemic control, these agents are showing promise in resolving steatohepatitis and slowing fibrosis progression, raising the question of whether dual-target incretin therapies may outperform GLP-1 receptor agonists alone. Why was this review needed? With multiple incretin-based agents now available or in development, clinicians need to understand whether dual agonists offer meaningful advantages over GLP-1 monotherapy and how they compare with other approved therapies such as resmetirom. What did the review show? • GLP-1 receptor agonists and dual incretin therapies consistently achieve high rates of MASH resolution. • Semaglutide significantly improved both steatohepatitis resolution and fibrosis in phase III studies. • Dual agonists such as tirzepatide, survodutide, and pemvidutide target complementary metabolic pathways and may provide greater reductions in hepatic fat and body weight. • In the IMPACT phase II trial, pemvidutide achieved MASH resolution in over half of treated patients but did not significantly improve fibrosis after only 24 weeks. • Improvements in liver fat, liver enzymes, and several non-invasive fibrosis biomarkers were observed with pemvidutide. • Gastrointestinal adverse events remained the most common side effects and were generally manageable. • Longer-duration studies are needed to determine whether early metabolic improvements translate into meaningful fibrosis regression. Clinical Impact: Incretin-based therapies are becoming a major pillar of MASH treatment. Dual-target agents may provide additional metabolic benefits beyond GLP-1 monotherapy, but their long-term impact on fibrosis, treatment duration, and combination strategies remains to be established. Take-Home Message: Incretin therapies are reshaping the treatment of MASH. While dual-target agents appear biologically promising and achieve high rates of steatohepatitis resolution, whether two mechanisms are truly better than one for reversing liver fibrosis will require longer-term phase III evidence.

Metabolic Drivers of MASLD and MASH: Diabetologia | June 2026

Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are now recognized as systemic metabolic diseases rather than isolated liver disorders. This review integrates current knowledge on how hormonal, metabolic, inflammatory, and fibrotic pathways interact to drive disease progression. Why was this review needed? Despite major advances in understanding MASLD, the mechanisms linking obesity, insulin resistance, adipose dysfunction, and chronic inflammation to progressive liver fibrosis remain incompletely integrated. A comprehensive understanding is essential for developing precision therapies. What did the review show? • Insulin resistance is the central metabolic driver of MASLD and MASH progression. • Dysfunctional adipose tissue increases free fatty acid delivery to the liver, promoting hepatic steatosis and lipotoxicity. • Imbalance between insulin and glucagon disrupts glucose and lipid metabolism, accelerating liver injury. • Chronic glucotoxicity and lipotoxicity trigger hepatocyte injury and persistent low-grade inflammation (metaflammation). • Crosstalk between adipose tissue, the gut, and the liver amplifies immune activation and disease progression. • Activation of hepatic stellate cells is the key pathway leading to liver fibrosis. • Sex hormones and the gut–liver–adipose axis contribute to disease heterogeneity and individual susceptibility. • The review highlights multiple therapeutic targets across metabolic, hormonal, inflammatory, and fibrotic pathways. Clinical Impact: MASLD should be managed as a multisystem metabolic disease rather than a liver-specific disorder. Targeting insulin resistance, adipose dysfunction, hormonal imbalance, and chronic inflammation may help prevent progression to MASH and advanced fibrosis. Take-Home Message: MASLD and MASH result from complex interactions between metabolic dysfunction, hormonal imbalance, inflammation, and fibrosis. Understanding these interconnected pathways provides the foundation for precision medicine and the development of mechanism-based therapies that target disease progression rather than hepatic steatosis alone.

AREL1: A New Stellate-Cell Target in MASH Fibrosis: Nature Communications | June 2026

• Integrated single-cell and single-nucleus RNA sequencing identified a distinct hepatic stellate cell population associated with MASH-related fibrosis. • AREL1 emerged as a characteristic gene of this fibrogenic stellate-cell population and was selectively increased in MASH fibrosis. • Hepatic stellate cells are central drivers of liver fibrosis, but current therapies do not directly and selectively suppress their disease-associated activation. • Cholesterol increased AREL1 activity, providing a mechanistic link between the metabolic environment of MASH and stellate-cell activation. • AREL1 promoted fibrosis through the AREL1–ILK axis, leading to activation of the PI3K–AKT signaling pathway. • Stellate-cell-specific deletion of Arel1 markedly reduced liver fibrosis in male mouse models of MASH. • The investigators also developed vitamin A–modified lipid nanoparticles to deliver Arel1-targeted therapy directly to hepatic stellate cells. • Therapeutic knockdown of Arel1 using this targeted delivery system substantially improved MASH-related fibrosis in preclinical models. • The study supports a precision antifibrotic strategy that targets a specific pathogenic stellate-cell state rather than broadly suppressing liver inflammation. • The findings remain preclinical. Human safety, optimal dosing, durability, off-target effects, and efficacy across different fibrosis stages require further evaluation. • The report is currently an unedited early-access manuscript, so details may change during final publication. Bottom line: AREL1 links cholesterol exposure to hepatic stellate-cell activation through ILK–PI3K–AKT signaling. Targeted AREL1 silencing may offer a new cell-specific therapeutic strategy for MASH-related liver fibrosis.

Ultra-Processed Foods, MASLD and Cognitive Ageing: Nutrients | June 2026

• This review proposes a processing-centred gut–liver–brain axis, positioning MASLD as a metabolic amplifier between ultra-processed food exposure and cognitive decline. • Ultra-processed foods are not simply high in sugar, fat, or salt; industrial processing disrupts the food matrix, accelerates eating, displaces fibre-rich microbial substrates, and introduces additives and processing-derived compounds. • Higher ultra-processed food intake has been associated with hepatic steatosis, MASLD, cognitive impairment, stroke, and dementia-related outcomes, although causality remains unproven. • Proposed mechanisms include gut microbial dysbiosis, impaired intestinal barrier integrity, metabolic endotoxaemia, altered bile acid signalling, hepatic lipotoxicity, insulin resistance, and systemic inflammation. • The liver may amplify gut-derived signals and transmit inflammatory, vascular, endocrine, and metabolic effects to the brain. • Altered FXR and TGR5 bile acid signalling provides a biologically plausible communication pathway connecting the microbiome, liver metabolism, and neuroimmune function. • MASLD shares several drivers of cognitive aging, including obesity, diabetes, dyslipidaemia, endothelial dysfunction, and chronic low-grade inflammation. • Ultra-processed foods may also promote passive overconsumption through rapid eating, hyperpalatability, altered texture, and reduced satiety. • Many proposed pathways overlap with general cardiometabolic disease, making it difficult to isolate the independent effect of food processing itself. • Current evidence is mainly observational and mechanistic; the review does not establish that ultra-processed foods directly cause dementia or that treating MASLD prevents cognitive decline. • Clinically, replacing ultra-processed foods with minimally processed, fibre-rich foods may simultaneously support liver, metabolic, vascular, and cognitive health. • Future studies should combine dietary substitution trials with liver imaging, microbiome and metabolomic profiling, bile acid and inflammatory biomarkers, neuroimaging, and longitudinal cognitive assessment. Bottom line: Ultra-processed foods may disrupt gut–liver–brain communication, with MASLD acting as a hepatic amplifier of metabolic and inflammatory signals relevant to cognitive aging. The concept is compelling but requires prospective mechanistic and intervention studies.

Updated Care Pathway for MASLD Risk Stratification : Gastroenterology | Jul 2026

Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) has emerged as one of the most prevalent chronic liver diseases worldwide, affecting nearly one-third of adults and a majority of individuals with type 2 diabetes. Beyond liver-related complications, MASLD is strongly associated with cardiovascular disease, reduced quality of life, and increased mortality. Recent advances in nomenclature, noninvasive diagnostics, and therapeutic options have necessitated an updated, practical framework for patient management. Problem Statement: Despite the growing burden of MASLD, many patients remain undiagnosed or are identified only after developing advanced fibrosis or cirrhosis. Variability in screening practices, limited access to specialist care, and uncertainty regarding risk stratification contribute to delayed diagnosis and suboptimal management. Clinicians require a structured and evidence-based approach that can be applied across primary care and specialty settings. Summary: This updated AGA Clinical Care Pathway provides a comprehensive framework for the identification, risk stratification, and management of patients with MASLD and metabolic dysfunction–associated steatohepatitis (MASH). Developed by a multidisciplinary international panel, the pathway incorporates recent advances in disease nomenclature, noninvasive fibrosis assessment, and therapeutic management. The document emphasizes that MASLD should be actively considered in patients with metabolic risk factors, particularly type 2 diabetes, obesity, and cardiometabolic disease. A central focus of the pathway is the early identification of patients at risk for advanced fibrosis using noninvasive tests, allowing efficient triage and reducing unnecessary specialist referrals. The updated recommendations also reinforce the importance of comprehensive cardiometabolic risk management, recognizing cardiovascular disease as the leading cause of mortality in this population. In addition, the pathway integrates evolving evidence regarding pharmacologic therapies, obesity management, and multidisciplinary care models. Practical implementation strategies are provided to facilitate adoption across diverse healthcare settings and improve care coordination among primary care providers, endocrinologists, hepatologists, gastroenterologists, cardiologists, and obesity specialists. Overall, this updated pathway reflects the transition of MASLD from a liver-focused condition to a multisystem metabolic disease requiring coordinated risk-based management. By promoting earlier detection, standardized risk assessment, and targeted intervention, the pathway aims to improve liver-related outcomes while addressing the broader cardiometabolic risks faced by patients with MASLD.